12:00 AM
Sep 23, 2013
 |  BioCentury  |  Emerging Company Profile

Carmenta: Preempting preeclampsia

Carmenta's diagnostic could confirm preeclampsia, speeding treatment decisions

The diagnosis of preeclampsia in pregnant women currently relies on detection of symptoms that do not reliably differentiate it from other conditions, thereby delaying treatment decisions. Carmenta Bioscience Inc.'s panel of serum markers could solve this problem by confirming a diagnosis of preeclampsia quickly and accurately.

Preeclampsia occurs in about 5% of pregnant women and can lead to life-threatening seizures (eclampsia). The condition is usually diagnosed in the second or third trimester when clinical symptoms of hypertension and proteinuria appear.

To confirm the diagnosis, physicians follow patients to see whether the symptoms worsen, delaying treatment decisions for several weeks or more.

According to President and CEO Matthew Cooper, genomics and proteomics studies in pregnant women by Stanford University School of Medicine researchers in 2011 identified "a couple dozen serum markers that differentiated preeclampsia from healthy pregnancy."

SPARK, the school's translational science program, funded the project's development. Cooper, then a member of SPARK's advisory...

Read the full 753 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >